Microcap Conatus teams up with pharma giant Novartis on NASH drug, shares rocket up
The microcap biotech Conatus Pharmaceuticals $CNAT just struck a licensing deal with Novartis for its lead drug that’s worth about as much as its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
